针对癌症中的 PI3K 信号通路。
Targeting the PI3K signaling pathway in cancer.
机构信息
Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
出版信息
Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.
摘要
磷酸肌醇 3-激酶（PI3K）途径在多种不同的人类癌症中被激活，该途径的抑制剂作为抗癌治疗药物正在积极开发中。在这篇综述中，我们讨论了支持在遗传和临床定义的癌症中使用 PI3K 途径抑制剂的数据。这篇综述重点介绍了它们作为单一药物以及与其他靶向治疗（特别是针对 MEK-ERK 信号通路的靶向治疗）联合使用的疗效。
相似文献
1
Targeting the PI3K signaling pathway in cancer.针对癌症中的 PI3K 信号通路。
Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.
2
Targeting the PI3K signaling pathway in cancer therapy.针对癌症治疗中的 PI3K 信号通路。
Expert Opin Ther Targets. 2012 Jan;16(1):121-30. doi: 10.1517/14728222.2011.644788. Epub 2012 Jan 12.
3
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.联合选择性 PI3K/mTOR 和 RAS/ERK 通路抑制剂抑制卵巢癌细胞生长的协同作用。
Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.
4
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
5
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Ras/Raf/MEK/ERK和PI3K/PTEN/Akt/mTOR级联抑制剂：突变如何导致治疗耐药以及如何克服耐药
Oncotarget. 2012 Oct;3(10):1068-111. doi: 10.18632/oncotarget.659.
6
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.PI3K 通过 Rac-GEF，P-Rex1 调节乳腺癌中的 MEK/ERK 信号。
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.
7
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.靶向 PI3K/mTOR 可克服抗 HER2 治疗的耐药性，而不依赖于 AKT 的反馈激活。
Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.
8
Targeting PI3K Signaling in Combination Cancer Therapy.联合癌症治疗中靶向PI3K信号通路
Trends Cancer. 2017 Jun;3(6):454-469. doi: 10.1016/j.trecan.2017.04.002. Epub 2017 May 14.
9
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.乳腺癌中 HER2-PI3K 信号的最佳靶向治疗：机制见解与临床意义。
Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21.
10
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.PI3K 和 MEK 抑制剂联合治疗可使 PIK3CA 突变性乳腺肉瘤样癌 PDX 模型获得持久缓解。
J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y.
引用本文的文献
1
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.肝细胞癌中的代谢重编程：免疫逃逸机制及治疗意义
Front Immunol. 2025 Apr 30;16:1592837. doi: 10.3389/fimmu.2025.1592837. eCollection 2025.
2
Modulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression.用BML-260调节磷酸酶DUSP22可通过不依赖Akt的JNK-FOXO3a抑制改善骨骼肌萎缩。
EMBO Mol Med. 2025 Apr 22. doi: 10.1038/s44321-025-00234-2.
3
New job for an old tool: PI3Kβ phosphorylates OGT to regulate acetyl-CoA in glioblastoma.旧工具的新任务：PI3Kβ磷酸化OGT以调节胶质母细胞瘤中的乙酰辅酶A
Trends Cell Biol. 2025 May;35(5):361-363. doi: 10.1016/j.tcb.2025.04.002. Epub 2025 Apr 16.
4
Tumor suppressive effect of low-frequency repetitive transcranial magnetic stimulation on glioblastoma progression.低频重复经颅磁刺激对胶质母细胞瘤进展的肿瘤抑制作用
Neurotherapeutics. 2025 Jul;22(4):e00569. doi: 10.1016/j.neurot.2025.e00569. Epub 2025 Mar 27.
5
Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models.阿哌利西（PI3K抑制剂）与瑞博西尼（CDK4/6抑制剂）联合应用在临床前结直肠癌模型中的协同作用
Int J Mol Sci. 2024 Dec 10;25(24):13264. doi: 10.3390/ijms252413264.
6
MTHFD1 Regulates Autophagy to Promote Growth and Metastasis in Colorectal Cancer via the PI3K-AKT-mTOR Signaling Pathway.MTHFD1 通过 PI3K-AKT-mTOR 信号通路调控自噬促进结直肠癌细胞的生长和转移。
Cancer Med. 2024 Nov;13(22):e70267. doi: 10.1002/cam4.70267.
7
How lactate affects immune strategies in lymphoma.乳酸如何影响淋巴瘤中的免疫策略。
Front Mol Biosci. 2024 Oct 11;11:1480884. doi: 10.3389/fmolb.2024.1480884. eCollection 2024.
8
Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.竞争性内源RNA调控互作网络：从RNA世界到指导癌症干细胞发育的信号通路的信息
Heliyon. 2024 Jul 26;10(15):e35208. doi: 10.1016/j.heliyon.2024.e35208. eCollection 2024 Aug 15.
9
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.TWEAK/Fn14 信号驱动的超级增强子重编程促进三阴性乳腺癌的促转移代谢重排。
Nat Commun. 2024 Jul 5;15(1):5638. doi: 10.1038/s41467-024-50071-z.
10
Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway.抑制ABI2泛素化依赖性降解通过下调PI3K/Akt信号通路抑制三阴性乳腺癌细胞生长。
Cancer Cell Int. 2024 Jun 27;24(1):222. doi: 10.1186/s12935-024-03407-0.
本文引用的文献
1
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.PI3K抑制后HER2和EGFR依赖型癌症中凋亡的差异诱导
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.
2
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.确定癌症中PI3K和MAPK信号通路单一及联合抑制的基因型依赖性疗效。
Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351-6. doi: 10.1073/pnas.0907325106. Epub 2009 Oct 5.
3
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.靶向癌症中的PI3K信号通路：机遇、挑战与局限
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
4
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.人类癌症中致癌性PIK3CA突变下游的非AKT依赖性信号传导。
Cancer Cell. 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012.
5
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.MEK和磷脂酰肌醇3激酶抑制剂在基底样乳腺癌模型中的体内抗肿瘤活性。
Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.
6
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.不依赖配体的HER2/HER3/PI3K复合物被曲妥珠单抗破坏，并被PI3K抑制剂GDC-0941有效抑制。
Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020.
7
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.基底亚型和丝裂原活化蛋白激酶/细胞外信号调节激酶（MEK）-磷脂酰肌醇3-激酶反馈信号决定乳腺癌细胞对MEK抑制的敏感性。
Cancer Res. 2009 Jan 15;69(2):565-72. doi: 10.1158/0008-5472.CAN-08-3389.
8
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.磷脂酰肌醇-3-激酶途径中的突变预示着抑制剂PX-866的抗肿瘤活性，而致癌性Ras是耐药性的主要预测指标。
Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.
9
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.有效使用PI3K和MEK抑制剂治疗携带Kras G12D突变和PIK3CA H1047R突变的小鼠肺癌。
Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.
10
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.NVP-BEZ235，一种双PI3K/mTOR抑制剂，可阻止PI3K信号传导并抑制具有激活PI3K突变的癌细胞的生长。
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
Zotero 插件